Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Penile Prosthesis Implantation

  • Author: Richard A Santucci, MD, FACS; Chief Editor: Bradley Fields Schwartz, DO, FACS  more...
 
Updated: Jan 15, 2014
 

Background

Potency has always been something special in human culture. Its effects even have been intertwined within early Common and Church laws in Europe. For instance, laws required that marriages be consummated; unconsummated marriages were grounds for annulment. Considering this happened in an age when divorce was extremely rare shows the magnitude of the "offense" of impotency.

Impotency at that time had far-reaching consequences, which included social stigmatization, societal standing within the community, and legal ramifications on such issues as claims on wills and considerations of the legitimacy of heirs. Although less drastic today, potency still plays a large part in men's self-image and affects the relationship with their partners.

Before 1960, urologic therapy for erectile dysfunction (ED) was rare. ED was branded a psychiatric disorder with little surgical role. More recently, the pathophysiology of male sexual dysfunction has been elucidated, and both medical and surgical treatments of ED are now common.

Next

History of the Procedure

The history of modern ED surgery began with the development of the inflatable penile prosthesis by Scott and Bradley in the early 1970s.[1] This surgical treatment became the treatment of choice in men with significant organic ED. Although the popularity of the inflatable penile prosthesis increased during that time, its design suffered from unacceptable failure rates and the need for surgical revision. Because of this, some urologists began using semirigid intracorporal devices to circumvent the reliability problems of early inflatables.

Today, penile prostheses have proven to be both reliable and durable, with approximately 20,000-30,000 devices implanted annually worldwide. In a 1996 survey, approximately 21,000 prostheses were implanted in North America, with another 5000 worldwide. With new social awareness regarding ED, many experts believe that future device implantations will become more prevalent because of failing medical therapy.

Previous
Next

Problem

As defined by Pearman, an early leader in this field, ED is the inability to produce and maintain a functional erection because of pathology of the nervous or vascular system or deformation of the penis.[2] The surgical treatment of ED largely involves the placement of a penile prosthesis, although penile revascularization procedures have been described.

The most fundamentally basic prosthesis is the semirigid rod prosthesis, which consists of 2 rodlike cylinders that are implanted in the corpora cavernosa. The prosthesis can have a mechanically jointed "backbone" or have a malleable one that allows the phallus to be dressed in the upward or downward position. This prosthesis is generally considered for patients who are significantly obese, who have limited manual dexterity, or in whom abdominal hardware such as reservoir balloons cannot be implanted (ie, patients undergoing extensive abdominal/perineal surgery and those receiving peritoneal dialysis).

Models

See the list below:

  • Mechanical rods: Dura II (AMS [formerly produced by Timm Medical Technologies]) prostheses have a series of polyethylene segments that articulate in a ball and socket arrangement and are held in place by a central spring. A silicone membrane covers these devices, and they come in 2 width sizes—10 mm and 12 mm. The standard length of 13 cm is augmented by adding proximal and distal tip extenders.
  • Malleable rods (650/600M [AMS]; Acu-Form [Mentor])
    • The AMS models consist of a wire core surrounded by polyester covering and silicone outer jacket. Model 600 is available in 9.5-mm and 11.5-mm width sizes, and the model 650 is available in 11-mm and 13-mm width sizes. Lengths range from 12–20 cm and can vary with tip extenders.
    • The Mentor Acu-Form has a silver wire backbone with a silicone elastomer outer coat and is available in widths of 9.5 mm, 11 mm, and 13 mm. Cylinder lengths range from 14-27 cm. This prosthesis is chosen for its simplicity of usage and durability due to fewer vital moving parts.
  • Unitary inflatable penile prosthesis (Dynaflex [AMS])
    • In 1990, the Dynaflex model was introduced as a more robust replacement of the Hydroflex. It is a paired cylinder with all operating components contained within each device, and it consists of the distal tip, central chamber, and proximal reservoir. Rigidity is achieved by pumping 2-3 mL of liquid into the central chamber from the reservoir. Bending the cylinder 55° or more from horizontal operates a pressure switch to deflate the device and to return fluid back to the reservoir. These cylinders are available in 2 widths—11 and 13 mm—and various lengths.
    • This was a good attempt to allow for inflation and deflation in a self-contained unit; however, a patient with a broad penis usually has incomplete filling by the Dynaflex cylinders and, thus, may experience shifting and buckling of the device during intercourse. Some patients complain that it is difficult to inflate because of 2 separate distal pumps. In addition, this device is not suitable for patients with a history of distal urethral erosion because of pressure applied to tissue while the implant is operated.
  • Two-piece inflatable devices (Ambicor [AMS] and Mark II [Mentor] [production discontinued in 2000])
    • These devices are marketed to improve the ease of surgical implantation by eliminating the need for reservoir placement in the abdominal region. These prostheses consist of 2 inflatable cylinders that are inserted into the corporal bodies and are connected to a pump-reservoir located in the scrotum. The drawback of these devices is the limited reservoir capacity of 15-20 mL, which is available not only for cycling the 2 cylinders for full rigidity but also for allowing for flaccidity. As much as 5-10 mL of fluid is left in the cylinders during the flaccid state because of limited reservoir space. Patients with larger penises criticize these devices for insufficient volume to fully inflate the cylinders, and those with smaller penises complain of difficulty completely deflating the cylinders because of the limited reservoir capacity and resulting residual cylinder fluid.
    • These prostheses should be considered for patients in whom reservoir implantation is difficult or contraindicated, such as those who have undergone pelvic exenteration or renal transplantation.
  • Three-piece inflatable devices (700 series [AMS], Alpha 1, and Titan [Mentor])
    • These devices tend to be more complex and consist of 2 inflatable cylinders placed in the corporal bodies, a small pump that resides in the scrotum, and a large fluid reservoir located in the abdomen. Three-piece prostheses prove to be the most satisfactory devices because they produce the most natural-appearing phallus in both the inflated and deflated states, produce good rigidity (even for larger penises), and offer good flaccidity for social dress. In addition, the flaccid state of the 3-piece allows removal of pressure against the corpora and tunica albuginea. Thus, patients with diabetes, previous implantation extrusion, and previous infections may benefit from this type of inflatable device.
    • The AMS 700 series offers the Ultrex model, which allows for girth and distal expansion, while the CX imparts only girth expansion. The CX line is most applicable to patients with scar tissue or those with a tendency for penile curvature upon tumescence. A new innovation in this line includes the InhibiZone antibiotic surface treatment (rifampin and minocycline hydrochloride), which has been shown to decrease the incidence of infection by roughly half compared with uncoated devices (down to 0.7% in one large study[3] ).
    • The Bioflex cylinders used in the Alpha 1 and Titan models from Mentor allow expansion in girth with minimal axial elongation. These have proven to be very durable and resistant to cylinder aneurysm formation. The newer Titan model is identical to the Alpha 1, with the addition of a hydrophilic coating (polyvinylpyrrolidone), which decreases bacterial attachment and enables antibiotic absorption onto the implant when soaked in antibiotic solution prior to implantation. Preliminary data suggest a significant reduction in infection compared with the noncoated model. Both Mentor 3-piece devices now come equipped with a reservoir lockout valve, which has been shown to decrease the risk of autoinflation.

In summary, selection of the appropriate device for the individual patient is very important. Considerations include patient's preference and underlying medical condition, surgeon's preference, and cost of the device. The advantages of the semirigid devices include easier placement, less dependence on patient manual dexterity, a smaller risk of mechanical failure, and lower cost. The disadvantages include higher risk for device erosion, less concealability, and inability to change girth. The semirigid devices may suit patients who have dexterity problems such as those with severe arthritis and others with hand limitations that interfere with working a scrotal pump.

The ideal penile prosthesis would result in a normal-appearing penis when flaccid and erect. Younger patients with good hand dexterity often choose the 3-piece prothesis. This is especially important for those engaged in social settings, such as health club showers, or who wear form-fitting clothes. However, prospective patients should be counseled that penile prostheses do not achieve the full length achieved by natural erections.

Previous
Next

Epidemiology

Frequency

Studies regarding the incidence of ED have proven difficult. Many experts believe that currently available data are often unreliable, especially when based on patient self-reporting. One study by Massey et al (1984) mentions ED incidence as 17 new cases per 100,000 man-years.[4] In other studies, as many as 40% of men interviewed reported some kind of sexual dysfunction. Interestingly, few respondents indicated that the problem was abnormal for their age, and even fewer stated they would seek medical treatment for their sexual problem.

Among men who seek medical help for sexual dysfunction, ED is the single most common presenting problem. It accounts for more than one half of all sexual complaints.

The Massachusetts Male Aging Study by Feldman and colleagues (1994) estimates that men in their early fifth decade of life have a 20% ED rate, and, by their eighth decade of life, close to 45% of men have impotence problems. They further estimate that, between the fifth and seventh decades of life, the probability of having complete impotence triples.[5]

Previous
Next

Etiology

The causes of impotence are multifactorial, but diabetes and vascular disease are the most common etiologies. They are usually classified as hormonal, neurologic, psychological, arterial (ie, insufficiency), and venous (ie, venous incompetence).

Injury to nerves and blood vessels can result from trauma, radiation therapy, pelvic surgeries (including prostatectomy), and longstanding medical conditions (eg, diabetes, hypertension).

Neurologic causes include multiple sclerosis, tabes dorsalis, and other degenerative disease of the nervous system. Hormonal imbalance or deficiency, such as primary testicular failure, Cushing disease, Addison disease, and diabetes mellitus, can cause ED.

Sometimes, adverse effects of drugs such as parasympathetic- and sympathetic-blocking agents, antihistamines, and drugs of abuse may be a cause. Peyronie disease, which is characterized by scarring of the underlying fibrous covering of the erection bodies of the penis, can cause curvature that prevents adequate penetration and requires surgical intervention.

Previous
Next

Pathophysiology

Penile tumescence is a complex integration of vascular and neurophysiologic events that culminates in the accumulation of blood under pressure. Fundamentally, the erectile components are surrounded by a thick fibroelastic sheath called the tunica albuginea, which allows a hydraulic effect in which intrapenile blood volume may increase 8-fold. The effect is an increase in intracorporal pressure that approaches systemic blood pressure and produces both penile volume and rigidity.

Blood supply to the penis is derived from the internal pudendal artery, which is a branch of the internal iliac artery. The internal pudendal artery becomes the common penile artery, which then branches into the bulbourethral, cavernosal, and the dorsal penile arteries. Tumescence depends most on the cavernosal arteries.

Penile tumescence is caused by microvascular events in the corpora cavernosa, which allow inflow of blood but restrict outflow. When blood enters the corpora cavernosa, it pressurizes the lacunar spaces within the spongy tissue of the corpora and translates this pressure to the tunica sheath. This pressure impedes venous drainage and results in blood being trapped in the penis and penile erection.

These microvascular events are triggered by neurologic events, which themselves are triggered by sexual stimuli. The parasympathetic nervous system offers the excitatory input to the penis and allows for the vasodilation of the penile vasculature. The parasympathetics originate from sacral spinal cord segments 2-4 and travel via the pelvic plexus into the pelvic nerve. The pelvic nerve joins the sympathetic nerve fibers that originate in the thoracic spine and together become the cavernous nerves as they exit the pelvic plexus. The cavernous nerves travel along the posterolateral aspect of the prostate and are susceptible to damage during pelvic surgery, such as a radical prostatectomy.

The sympathetic nervous system controls ejaculation and detumescence and has a partial role in maintaining erections. Sympathetic preganglionic nerve fibers originate from the intermediolateral cell column to form the thoracolumbar sympathetic pathway (thoracic segment 9 to lumbar segment 2). These preganglionic fibers exit the spinal cord as ventral roots via white rami to become part of the sympathetic chain ganglia. They synapse onto sacral and caudal lumbar ganglion cells. These cells then send postganglionic axons via gray rami to diverge into the pelvic, cavernous, and pudendal nerves that serve the urogenital tract.

Somatic pathways are important for penile sensation and ejaculation. Sensory afferents from the pudendal nerve become the dorsal nerve of the penis, which enters the urogenital diaphragm to innervate the penile skin, prepuce, and glans. The input from these sensory fibers helps maintain erections. These sensory fibers can be damaged by aging and diabetes.

Somatic efferents also originate from the pudendal nerve to innervate motor fibers of the pelvic floor and the bulbocavernous and ischiocavernous muscles. Contraction of these muscles occurs during ejaculation and influences the quality of erections.

Complex synaptic connections of the somatic and visceral neurons facilitate the coordination of erection and ejaculation. The parasympathetic and sympathetic nervous systems were once believed to be in an antagonistic balance to achieve erections; however, parasympathetic and sympathetic pathways are now known to act synergistically. Moreover, well-studied neurochemicals, such as acetylcholine and noradrenaline, are joined by newly discovered ones, such as nitric oxide, vasoactive intestinal peptide, neuropeptide Y, calcitonin gene-related peptide, substance P, and serotonin, which are believed to contribute to normal erectile function.

Erectile function is a very complex and highly tiered system. Disruption along this chain of events can cause varying degrees of ED.

Previous
Next

Presentation

See Etiology.

Previous
Next

Indications

Penile prosthesis placement is indicated in a motivated patient with erectile dysfunction (ED) who desires reconstitution of penile function adequate for intercourse and in whom conservative treatment has failed.

Conservative treatments may include oral medications, such as sildenafil (Viagra); intracavernosal injections of vasoactive substances, such as prostaglandin E1 (PGE1); intraurethral deposition of PGE1 pellets (medicated urethral system for erection [MUSE]); and vacuum-assist devices. Recently, Rosenberg et al (2009) reported on successful results with the phosphodiesterase-5 inhibitor vardenafil. Vardenafil provided erection duration that was statistically superior to that conferred by placebo in men with ED, leading to successful intercourse.[6]

Patients with sickle cell anemia who have stuttering priapism and/or cavernosal scarring are also potential candidates for inflatable penile prosthesis, which offers not only a cure for their priapism but also a close approximation to normal appearance and function.

Men with Peyronie disease, which is characterized by a fibrous scar of the tunica albuginea, who have penile curvature may benefit from an inflatable penile prosthesis. The hydraulic effect of the prosthesis can frequently overcome the scar and help greatly to straighten the penis for adequate intercourse. Surgeons can also place penile prostheses after excision and grafting of the Peyronie plaque.

As discussed below, many preoperative tests can be used to assess ED (see Lab Studies). However, the actual practice of evaluating ED proves to be not only quite varied but also controversial. It depends on the practice of the individual urologists. Some practitioners argue that etiology is insignificant and that ED is treated in a stepwise fashion—from least to progressively more invasive treatments. Others argue that, from a medicolegal standpoint, basic evaluation and documentation should be instituted regarding the diagnosis of ED.

Physicians whose practices focus on treating ED say that many patients who seek treatment are interested in finding the etiology. The more involved and knowledgeable the patient becomes, the more he is willing to continue a particular treatment and report greater satisfaction. Basic tests such as a testosterone level assessment can help diagnose primary or secondary hypogonadism and can allow for possible medical treatment without surgical intervention.

In the authors' experience, a screening testosterone level should be obtained and ED diagnosis confirmed with ultrasound Doppler scan (at the very minimum). In addition to a careful history taking, physical examination, and the combination of biochemical test or tests with radiographic/physical findings, the diagnosis of ED is more reassuring to both patient and physician. Basic evaluation can prevent unwanted and unnecessary intervention.

Previous
Next

Relevant Anatomy

To understand the relevant anatomy of erectile function is to understand the tunica albuginea. It is the tough covering of the corpora cavernosa and consists of inner circular layers with intracavernosal pillars that help tether the corporal bodies from overexpansion. Outer longitudinally arranged fibers run from the glans penis to the proximal crura at the base of the penis.

The tunica albuginea is made of elastic tissue with embedded collagen fiber that offers expansile capability and rigidity.

The thinnest area of the tunica is at the ventral 5- and 7-o'clock positions, where the longitudinal outer layers are thinnest. This becomes important intraoperatively during cavernosal dilation because the dilator can extrude out of the corporal body. Postoperatively, the prostheses can herniate out in these weakened regions of the tunica.

Emissary veins run obliquely between the inner and outer layers of the tunica. These veins serve to drain the corporal bodies and are important during erection. Also important is that the septum between the paired corporal bodies is incomplete and has good vascular communication. This communication is why vasoactive substances, such as PGE1, injected intracavernosally into one corporal body elicit an equal response from the contralateral side.

Arterial supply

The main arterial vascular supply to the penis comes from the internal pudendal artery, which is a branch of the internal iliac artery. The vascular anatomy of the internal pudendal artery varies greatly, and many men have accessory internal pudendal arteries. This circumstance can explain why some men with discrete obstruction of their pudendal arteries can still achieve erections.

The internal pudendal becomes the common penile artery, which branches into the dorsal, bulbourethral, and cavernous arteries. The cavernous or cavernosal artery plays the most important role in erectile function because it gives off the helicine arterioles, which supply the spongy trabecular tissue that stores and traps blood for erection. These helicine arterioles are the gatekeepers for erections, and their dilation is the aim of many vasoactive drugs.

Venous drainage

The erectile spongy tissue is drained by venules that later coalesce to form the subtunical venous plexus before exiting the tunica albuginea as emissary veins. After surfacing from the tunica, they eventually form the circumflex, periurethral, and superficial dorsal veins.

Previous
Next

Contraindications

Some have listed psychogenic erectile dysfunction (ED) as a contraindication to penile prosthesis implantation. However, patients with severe longstanding psychogenic ED that is resistant to therapy might be considered for implantation as long as they understand the treatment is permanent. Nonetheless, the patient's mental health professional must be consulted prior to serious consideration of penile prosthesis implantation. Psychogenic ED is usually diagnosed based on results from a careful sexual history and diagnostic testing such as nocturnal penile tumescence (NPT) monitoring. Good morning erections with highly variable erection activity suggest a psychogenic factor.

The clinician may also consider the patient's reliability for follow-up care, as well as his manual dexterity. If the patient cannot operate his device, he must have a supportive and willing partner who can help. As mentioned above, the ability to operate the device must be considered when the type of device is chosen. The semirigid devices require less manipulation to operate.

Penile prosthesis implantation should not be performed in the presence of any systemic, cutaneous, or urinary tract infections. Patients with active or chronic infectious processes such as decubitus ulcers and venous stasis ulcers are at high risk for device seeding. In addition, no evidence of dermatitis, wounds, or other cutaneous lesions in the operative field should be present.

Conservative management regarding replacement of an infected prosthesis has mandated removal of the infected prosthesis with a delayed interval, usually 3-6 months, to allow adequate healing and eradication of the offending microorganism before replacement. However, rigorous salvage techniques have evolved that show success of one-stage replacement surgeries when no severe infection is present (eg, extrusion, gross purulence, immune compromise, severe diabetes).

Previous
 
 
Contributor Information and Disclosures
Author

Richard A Santucci, MD, FACS Specialist-in-Chief, Department of Urology, Detroit Medical Center; Chief of Urology, Detroit Receiving Hospital; Director, The Center for Urologic Reconstruction; Clinical Professor of Urology, Michigan State University College of Medicine

Richard A Santucci, MD, FACS is a member of the following medical societies: American College of Surgeons, Societe Internationale d'Urologie (International Society of Urology), American Urological Association

Disclosure: Nothing to disclose.

Coauthor(s)

Nazia Q Bandukwala, DO Fellow in Female Urology, Voiding Dysfunction, and Reconstructive Urology, Department of Urology, Memorial Hospital Florida

Nazia Q Bandukwala, DO is a member of the following medical societies: American Osteopathic Association, American Urological Association, American College of Osteopathic Surgeons, Sigma Sigma Phi

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Shlomo Raz, MD Professor, Department of Surgery, Division of Urology, University of California, Los Angeles, David Geffen School of Medicine

Shlomo Raz, MD is a member of the following medical societies: American College of Surgeons, American Medical Association, American Urological Association, California Medical Association

Disclosure: Nothing to disclose.

Chief Editor

Bradley Fields Schwartz, DO, FACS Professor of Urology, Director, Center for Laparoscopy and Endourology, Department of Surgery, Southern Illinois University School of Medicine

Bradley Fields Schwartz, DO, FACS is a member of the following medical societies: American College of Surgeons, Society of Laparoendoscopic Surgeons, Society of University Urologists, Association of Military Osteopathic Physicians and Surgeons, American Urological Association, Endourological Society

Disclosure: Nothing to disclose.

Additional Contributors

Gamal Mostafa Ghoniem, MD, FACS Professor and Vice Chair of Urology, Chief, Division of Female Urology, Pelvic Reconstructive Surgery, and Voiding Dysfunction, Department of Urology, University of California, Irvine, School of Medicine

Gamal Mostafa Ghoniem, MD, FACS is a member of the following medical societies: American Urogynecologic Society, International Continence Society, International Urogynaecology Association, Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction, American College of Surgeons, American Urological Association

Disclosure: Received honoraria from Astellas for speaking and teaching; Received grant/research funds from Uroplasty for none; Partner received honoraria from Allergan for speaking and teaching.

Acknowledgements

Yao-Jen Chang, MD Senior Resident, Department of Urology, Harper University Hospital, Wayne State University School of Medicine

Disclosure: Nothing to disclose.

Curtis N Crane, MD Fellow in Genitourinary Trauma and Reconstructive Urology, Wayne State University School of Medicine

Disclosure: Nothing to disclose.

Christopher Knopick, MD Resident Physician, Department of Urology, Detroit Medical Center

Disclosure: Nothing to disclose.

References
  1. Scott FB, Bradley WE, Timm GW. Management of erectile impotence. Use of implantable inflatable prosthesis. Urology. 1973 Jul. 2(1):80-2. [Medline].

  2. Pearman RO. Treatment of organic impotence by implantation of a penile prosthesis. J Urol. 1967 Apr. 97(4):716-9. [Medline].

  3. Carson CC 3rd. Efficacy of antibiotic impregnation of inflatable penile prostheses in decreasing infection in original implants. J Urol. 2004 Apr. 171(4):1611-4. [Medline].

  4. Massey FJ Jr, Bernstein GS, O'Fallon WM, Schuman LM, Coulson AH, Crozier R, et al. Vasectomy and health. Results from a large cohort study. JAMA. 1984 Aug 24-31. 252(8):1023-9. [Medline].

  5. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994 Jan. 151(1):54-61. [Medline].

  6. Rosenberg MT, Adams PL, McBride TA, Roberts JN, McCallum SW. Improvement in duration of erection following phosphodiesterase type 5 inhibitor therapy with vardenafil in men with erectile dysfunction: the ENDURANCE study. Int J Clin Pract. 2009 Jan. 63(1):27-34. [Medline]. [Full Text].

  7. Cilurzo P, Canale D, Turchi P, Giorgi PM, Menchini Fabris GF. [The Rigiscan system in the diagnosis of male sexual impotence]. Arch Ital Urol Nefrol Androl. 1992 Jun. 64 Suppl 2:81-5. [Medline].

  8. Henry G, Houghton L, Culkin D, Otheguy J, Shabsigh R, Ohl DA. Comparison of a new length measurement technique for inflatable penile prosthesis implantation to standard techniques: outcomes and patient satisfaction. J Sex Med. 2011 Sep. 8(9):2640-6. [Medline].

  9. Pathak AS, Chang JH, Parekh AR, Aboseif SR. Use of Rectus Fascia Graft for Corporeal Reconstruction During Placement of Penile Implant. Urology. Jun 05. 65:1198-201.

  10. Mulcahy JJ. Long-term experience with salvage of infected penile implants. J Urol. 2000 Feb. 163(2):481-2. [Medline].

  11. Akin-Olugbade O, Parker M, Guhring P, Mulhall J. Determinants of patient satisfaction following penile prosthesis surgery. J Sex Med. 2006 Jul. 3(4):743-8. [Medline].

  12. Jarow JP, Nana-Sinkam P, Sabbagh M, Eskew A. Outcome analysis of goal directed therapy for impotence. J Urol. 1996 May. 155(5):1609-12. [Medline].

  13. Henry GD, Donatucci CF, Conners W, Greenfield JM, Carson CC, Wilson SK, et al. An Outcomes Analysis of over 200 Revision Surgeries for Penile Prosthesis Implantation: A Multicenter Study. J Sex Med. 2011 Nov 14. [Medline].

  14. Goldstein I, Newman L, Baum N, Brooks M, Chaikin L, Goldberg K, et al. Safety and efficacy outcome of mentor alpha-1 inflatable penile prosthesis implantation for impotence treatment. J Urol. 1997 Mar. 157(3):833-9. [Medline].

  15. Dhar NB, Angermeier KW, Montague DK. Long-term mechanical reliability of AMS 700CX/CXM inflatable penile prosthesis. J Urol. 2006 Dec. 176(6 Pt 1):2599-601; discussion 2601. [Medline].

  16. Lux M, Reyes-Vallejo L, Morgentaler A, Levine LA. Outcomes and satisfaction rates for the redesigned 2-piece penile prosthesis. J Urol. 2007 Jan. 177(1):262-6. [Medline].

  17. Wilson SK, Henry GD, Delk JR Jr, Cleves MA. The mentor Alpha 1 penile prosthesis with reservoir lock-out valve: effective prevention of auto-inflation with improved capability for ectopic reservoir placement. J Urol. 2002 Oct. 168(4 Pt 1):1475-8. [Medline].

  18. Abouassaly R, Angermeier KW, Montague DK. Risk of infection with an antibiotic coated penile prosthesis at device replacement for mechanical failure. J Urol. 2006 Dec. 176(6 Pt 1):2471-3. [Medline].

  19. Rajpurkar A, Al-Omar O, Hellstrom WJ, et al. Polypyrrolidone-coated bioflex decreases infection rate following penile prosthesis surgery. Int J Impot Res. 2003. 15:s163.

  20. Becher E, Borghi M, de Oca LM, et al. Improvement of penile glans engorgement in patients with penile implants using topical alprostadil. Int J Impot Res. 2003. 15:s11.

  21. Anderson P, Agarwal V, Soden F, Ralph D, Minhas S. Outcome from Penile Prostheses Revision Surgery: MP-04-126. Journal of Sexual Medicine. 2007. 4S2:146.

  22. Beutler LE, Scott FB, Rogers RR Jr, Karacan I, Baer PE, Gaines JA. Inflatable and noninflatable penile prostheses: comparative follow-up evaluation. Urology. 1986 Feb. 27(2):136-43. [Medline].

  23. Brinkman MJ, Henry GD, Wilson SK, Delk JR 2nd, Denny GA, Young M, et al. A survey of patients with inflatable penile prostheses for satisfaction. J Urol. 2005 Jul. 174(1):253-7. [Medline].

  24. Carson CC. Diagnosis, treatment and prevention of penile prosthesis infection. Int J Impot Res. 2003 Oct. 15 Suppl 5:S139-46. [Medline].

  25. Carson CC, Hodge GB, Anderson EE. Penile prosthesis in Peyronie's disease. Br J Urol. 1983 Aug. 55(4):417-21. [Medline].

  26. Carson CC, Mulcahy JJ, Govier FE. Efficacy, safety and patient satisfaction outcomes of the AMS 700CX inflatable penile prosthesis: results of a long-term multicenter study. AMS 700CX Study Group. J Urol. 2000 Aug. 164(2):376-80. [Medline].

  27. Chiang HS, Wu CC, Wen TC. 10 years of experience with penile prosthesis implantation in Taiwanese patients. J Urol. 2000 Feb. 163(2):476-80. [Medline].

  28. Drogo K. Montague and Kenneth W. Angermeier. Corporeal Excavation: New Technique for Penile Prosthesis Implantation in Men with Severe Corporeal Fibrosis. Urology. 2006. 67:1072-1075.

  29. Jarow JP. Risk factors for penile prosthetic infection. J Urol. 1996 Aug. 156(2 Pt 1):402-4. [Medline].

  30. Knoll LD, Furlow WL, Benson RC Jr. Management of Peyronie disease by implantation of inflatable penile prosthesis. Urology. 1990 Nov. 36(5):406-9. [Medline].

  31. Lotan Y, Roehrborn CG, McConnell JD, Hendin BN. Factors influencing the outcomes of penile prosthesis surgery at a teaching institution. Urology. 2003 Nov. 62(5):918-21. [Medline].

  32. Montague DK. Periprosthetic infections. J Urol. 1987 Jul. 138(1):68-9. [Medline].

  33. Montague DK, Angermeir KW. Surgical approaches for penile prosthesis implantation: penoscrotal vs infrapubic. Int J Impot Res. 2003 Oct. 15 Suppl 5:S134-5. [Medline].

  34. Montague DK, Jarow JP, Broderick GA, Dmochowski RR, Heaton JP, Lue TF, et al. Chapter 1: The management of erectile dysfunction: an AUA update. J Urol. 2005 Jul. 174(1):230-9. [Medline].

  35. Silverstein AD, Henry GD, Evans B, Pasmore M, Simmons CJ, Donatucci CF. Biofilm formation on clinically noninfected penile prostheses. J Urol. 2006 Sep. 176(3):1008-11. [Medline].

  36. Staerman FS, Menard JM, Faix AF, Tremeaux J. Penile Prosthesis and Impotence in Elderly Men: Results of a Multicenter Study After 79 Implantations: MP-088. Journal of Sexual Medicine. 2006. 3S5:432-433.

  37. Walsh PC, Retik AB, Vaughan ED, Wein AJ. Campbell's Urology. 8th ed. Philadelphia, Pa: WB Saunders Co; 2002. Vol 2:

 
Previous
Next
 
Exposure of the corpus cavernosum followed by placement of stay sutures in the walls of the corpus followed by corporotomy in anticipation of placing an intracavernosal rod. (Photograph courtesy of Chirpraya B. Dhabuwala, MD).
Proximal dilation of the corpus with Hegar dilator. (Photograph courtesy of Chirpraya B. Dhabuwala, MD)
Seating of the proximal portion of the prosthesis into the corpus. (Photograph courtesy of Chirpraya B. Dhabuwala, MD).
Seating the distal portion of the prosthesis into the distal corpus using the suture attached to the prosthesis. Previously, the suture has been passed out the glans penis using a Furlow inserter. (Photograph courtesy of Chirpraya B. Dhabuwala, MD).
Bluntly creating the subdartos pouch, which will house the pump. (Photograph courtesy of Chirpraya B. Dhabuwala, MD).
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.